Posted by Michael Wonder on 05 Jul 2024
Tagrisso with the addition of chemotherapy approved in the EU as new first-line treatment for patients with EGFR-mutated advanced lung cancer
5 July 2024 - Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months versus standard of care.
AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in the European Union for the first-line treatment of adult patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
